Helen Coster’s recent commentary in her new Forbes blog Good Work addresses the issue of how product development partnerships (PDPs) can develop and improve treatments for neglected diseases like malaria, leishmaniasis, and Chagas disease.
Coster notes, “These diseases affect the world’s poorest people, and they often get ignored by pharmaceutical companies for a simple economic reason: there is no way that considerable investment in research will be recouped in drug sales.â€
Coster’s entry highlights the work of some of the best-known PDPs, such as the Drugs for Neglected Disease Initiative, Global Alliance for Vaccines and Immunization, the International AIDS Vaccine Initiative and the Global Fund to Fight AIDS, Tuberculosis & Malaria. Coster also highlighted the significant funding of PDPs by The Bill and Melinda Gates Foundation.
In closing, Coster invites her readers to discuss the PDP approach to eradicating neglected diseases and what role, if any, the pharmaceutical industry, philanthropists and other global organizations should play in the fight.
Global Health Progress also believes that public-private product development partnerships are invaluable in expanding the capacity of research and development (R&D) on innovative drugs and vaccines for neglected diseases. These partnerships help by harnessing the technical expertise and resources of the private sector with the approach of universities, research institutes and other public organizations.
Via EPR Network
More Healthcare press releases
